Figure 1.

A marginal improvement in overall survival but lack of any significant effect of treatment with the c-MET inhibitor EMD1214063 for 8 or 11 weeks on tumor growth in the Met-β-catenin model. (A) Schematic illustrating the overall experimental design of the study. (B) Gross liver images show comparable morphology between the control and EMD1241063 groups, although this group showed a somewhat healthy appearance at 8 weeks as shown by lack of relative nodularity. (C) No significant difference in liver weight/body weight (LW/BW) ratio as an indicator of overall tumor burden between the control and EMD1214063 treatment groups overall or at 8 or 11 weeks individually [average ± standard deviation (SD)]. (D) Kaplan–Meier survival curve showing EMD1241063 treatment causing marginal but significant improvement in the overall survival by 1.5–2 weeks compared to the control treatment in the Met-β-catenin model (p = 0.0396). This was based on time to morbidity as indicated by greater than 3 g of liver weight due to excessive tumor burden. (E) Hematoxylin and eosin (H&E) staining of representative liver sections from the EMD1214063 group versus controls shows comparable microscopic foci.